FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2963923441> ?p ?o ?g. }

• W2963923441 endingPage "146" @default.
• W2963923441 startingPage "1" @default.
• W2963923441 abstract "Background Despite widespread use of therapies such as inhaled corticosteroids (ICSs), people with chronic obstructive pulmonary disease (COPD) continue to suffer, have reduced life expectancy and utilise considerable NHS resources. Laboratory investigations have demonstrated that at low plasma concentrations (1–5 mg/l) theophylline markedly enhances the anti-inflammatory effects of corticosteroids in COPD. Objective To determine the clinical effectiveness and cost-effectiveness of adding low-dose theophylline to a drug regimen containing ICSs in people with COPD at high risk of exacerbation. Design A multicentre, pragmatic, double-blind, randomised, placebo-controlled clinical trial. Setting The trial was conducted in 121 UK primary and secondary care sites. Participants People with COPD [i.e. who have a forced expiratory volume in 1 second (FEV 1 )/forced vital capacity (FVC) of < 0.7] currently on a drug regimen including ICSs with a history of two or more exacerbations treated with antibiotics and/or oral corticosteroids (OCSs) in the previous year. Interventions Participants were randomised (1 : 1) to receive either low-dose theophylline or placebo for 1 year. The dose of theophylline (200 mg once or twice a day) was determined by ideal body weight and smoking status. Primary outcome The number of participant-reported exacerbations in the 1-year treatment period that were treated with antibiotics and/or OCSs. Results A total of 1578 people were randomised (60% from primary care): 791 to theophylline and 787 to placebo. There were 11 post-randomisation exclusions. Trial medication was prescribed to 1567 participants: 788 in the theophylline arm and 779 in the placebo arm. Participants in the trial arms were well balanced in terms of characteristics. The mean age was 68.4 [standard deviation (SD) 8.4] years, 54% were male, 32% smoked and mean FEV 1 was 51.7% (SD 20.0%) predicted. Primary outcome data were available for 98% of participants: 772 in the theophylline arm and 764 in the placebo arm. There were 1489 person-years of follow-up data. The mean number of exacerbations was 2.24 (SD 1.99) for participants allocated to theophylline and 2.23 (SD 1.97) for participants allocated to placebo [adjusted incidence rate ratio (IRR) 0.99, 95% confidence interval (CI) 0.91 to 1.08]. Low-dose theophylline had no significant effects on lung function (i.e. FEV 1 ), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact. Hospital admissions due to COPD exacerbation were less frequent with low-dose theophylline (adjusted IRR 0.72, 95% CI 0.55 to 0.94). However, 39 of the 51 excess hospital admissions in the placebo group were accounted for by 10 participants having three or more exacerbations. There were no differences in the reporting of theophylline side effects between the theophylline and placebo arms. Limitations A higher than expected percentage of participants (26%) ceased trial medication; this was balanced between the theophylline and placebo arms and mitigated by over-recruitment ( n = 154 additional participants were recruited) and the high rate of follow-up. The limitation of not using documented exacerbations is addressed by evidence that patient recall is highly reliable and the results of a small within-trial validation study. Conclusion For people with COPD at high risk of exacerbation, the addition of low-dose oral theophylline to a drug regimen that includes ICSs confers no overall clinical or health economic benefit. This result was evident from the intention-to-treat and per-protocol analyses. Future work To promote consideration of the findings of this trial in national and international COPD guidelines. Trial registration Current Controlled Trials ISRCTN27066620. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 23, No. 37. See the NIHR Journals Library website for further project information." @default.
• W2963923441 created "2019-07-30" @default.
• W2963923441 creator A5001203491 @default.
• W2963923441 creator A5009008744 @default.
• W2963923441 creator A5017361282 @default.
• W2963923441 creator A5019479654 @default.
• W2963923441 creator A5024774615 @default.
• W2963923441 creator A5030258071 @default.
• W2963923441 creator A5034189480 @default.
• W2963923441 creator A5038268634 @default.
• W2963923441 creator A5038285954 @default.
• W2963923441 creator A5038358028 @default.
• W2963923441 creator A5044898274 @default.
• W2963923441 creator A5047979811 @default.
• W2963923441 creator A5048090792 @default.
• W2963923441 creator A5052175038 @default.
• W2963923441 creator A5056602092 @default.
• W2963923441 creator A5061749118 @default.
• W2963923441 creator A5061925824 @default.
• W2963923441 creator A5070372650 @default.
• W2963923441 creator A5076371917 @default.
• W2963923441 creator A5079355438 @default.
• W2963923441 creator A5080457552 @default.
• W2963923441 date "2019-07-01" @default.
• W2963923441 modified "2023-09-24" @default.
• W2963923441 title "Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT" @default.
• W2963923441 cites W139152004 @default.
• W2963923441 cites W1503927696 @default.
• W2963923441 cites W1667375686 @default.
• W2963923441 cites W1850996803 @default.
• W2963923441 cites W1944345698 @default.
• W2963923441 cites W1971376483 @default.
• W2963923441 cites W1972110417 @default.
• W2963923441 cites W1972495472 @default.
• W2963923441 cites W1974745438 @default.
• W2963923441 cites W1976383676 @default.
• W2963923441 cites W1976722278 @default.
• W2963923441 cites W1979518810 @default.
• W2963923441 cites W1980580723 @default.
• W2963923441 cites W1986658269 @default.
• W2963923441 cites W1991297890 @default.
• W2963923441 cites W1995818471 @default.
• W2963923441 cites W1995964054 @default.
• W2963923441 cites W2001280173 @default.
• W2963923441 cites W2002472989 @default.
• W2963923441 cites W2002726093 @default.
• W2963923441 cites W2012042744 @default.
• W2963923441 cites W2013407710 @default.
• W2963923441 cites W2034497364 @default.
• W2963923441 cites W203985185 @default.
• W2963923441 cites W2041056515 @default.
• W2963923441 cites W2051806959 @default.
• W2963923441 cites W2052225778 @default.
• W2963923441 cites W2060057013 @default.
• W2963923441 cites W2061168784 @default.
• W2963923441 cites W2064201717 @default.
• W2963923441 cites W2071686284 @default.
• W2963923441 cites W2072042693 @default.
• W2963923441 cites W2074579548 @default.
• W2963923441 cites W2079267833 @default.
• W2963923441 cites W2080065572 @default.
• W2963923441 cites W2085243564 @default.
• W2963923441 cites W2085702628 @default.
• W2963923441 cites W2088040467 @default.
• W2963923441 cites W2091215576 @default.
• W2963923441 cites W2099368483 @default.
• W2963923441 cites W2107829061 @default.
• W2963923441 cites W2110040793 @default.
• W2963923441 cites W2111101263 @default.
• W2963923441 cites W2112103144 @default.
• W2963923441 cites W2112162293 @default.
• W2963923441 cites W2112674445 @default.
• W2963923441 cites W2116141140 @default.
• W2963923441 cites W2117543256 @default.
• W2963923441 cites W2117837864 @default.
• W2963923441 cites W2118249259 @default.
• W2963923441 cites W2120157356 @default.
• W2963923441 cites W2124518659 @default.
• W2963923441 cites W2125078269 @default.
• W2963923441 cites W2127938597 @default.
• W2963923441 cites W2129238234 @default.
• W2963923441 cites W2131160124 @default.
• W2963923441 cites W2132439698 @default.
• W2963923441 cites W2133024000 @default.
• W2963923441 cites W2133390997 @default.
• W2963923441 cites W2137397912 @default.
• W2963923441 cites W2138277216 @default.
• W2963923441 cites W2140036341 @default.
• W2963923441 cites W2141402647 @default.
• W2963923441 cites W2142724633 @default.
• W2963923441 cites W2149849734 @default.
• W2963923441 cites W2150171005 @default.
• W2963923441 cites W2150613910 @default.
• W2963923441 cites W2150729282 @default.
• W2963923441 cites W2157968241 @default.
• W2963923441 cites W2162038655 @default.
• W2963923441 cites W2162918753 @default.
• W2963923441 cites W2164011121 @default.

• next